Liver-Brain Model: Technical Data
Application Note, Validation Data, and Key Findings
Application Note
Modeling the Liver-Brain Axis with NANOSTACKS™
Download Full Application Note
This comprehensive note encompasses the characterization of differentiated HepaRG cells on NANOSTACKS™, providing insights into their behaviour and functionality. Additionally, it outlines the execution of neurotoxicity testing, shedding light on how NANOSTACKS™ facilitates the study of intercellular interactions and potential cross-effects between liver and brain cells.
Key Findings
Validation data demonstrating model performance
Stable CYP3A4 Activity
No statistically significant difference between timepoints, demonstrating maintained metabolic functionality.
Enhanced Sensitivity with Liver Component
Increased Sensitivity
26.8% lower IC50
The liver component increased the model's sensitivity to paclitaxel
Conclusions
HepaRG® Cell Performance
Differentiated HepaRG® cells adhered to NANOSTACKS™ and maintained their viability for 9 days of cell culture
HepaRG® cells were metabolically active, as CYP3A4 was detected across all timepoints
HepaRG® cells can successfully be incorporated into NANOSTACKS™
Liver-Brain Axis Model
HepaRG® were successfully cocultured with neural cell lines SH-SY5Y and U-138 MG, recapitulating the liver-brain axis
The triculture IC50 was 26.8% lower than the monoculture, suggesting that the liver component increased the model's sensitivity
Demonstrates feasibility for drug testing and studying liver-brain crosstalk in physiological and pathological conditions